尼日利亚镰状细胞贫血儿童卒中一级预防可行性试验(SPIN试验)
在尼日利亚卡诺开展可行性试验,评估羟基脲对经颅多普勒异常镰状细胞贫血儿童卒中一级预防的可接受性。88%(330/375)家庭同意筛查,87%(29/33)TCD异常者入组,平均红细胞体积从基线85.7 fl升至24个月95.5 fl,治疗组与对照组死亡率无显著差异(P=0.67)。
要点
- 88%(330/375)家庭同意筛查,87%(29/33)TCD异常儿童入组,无退出。
- 羟基脲固定中等剂量(约20 mg/kg/天)使平均红细胞体积从85.7 fl升至95.5 fl。
- 治疗组与对照组死亡率分别为2.69和1.81/100患者年,差异无统计学显著(P=0.67)。
核心结论
- 结果提供强证据表明家庭招募、保留和依从率高,可在非洲镰状细胞贫血儿童中开展羟基脲卒中一级预防的首次随机对照试验。
研究设计与样本
- 在尼日利亚卡诺开展的可行性试验;TCD异常(≥200 cm/s)的镰状细胞贫血儿童接受羟基脲固定中等剂量(约20 mg/kg/天),TCD<200 cm/s的对比组前瞻性随访。
主要发现
- 88%(330/375)家庭同意筛查,87%(29/33)TCD异常者入组,无参与者退出。
- 平均红细胞体积从基线85.7 fl升至24个月95.5 fl(并非所有交叉儿童均有24个月访视)。
- 对比组初始210例,其中4例出现TCD异常并开始羟基脲治疗;月度研究访视无遗漏(总计603次访视)。
- 治疗组与对比组分别发生2例和10例死亡,死亡率分别为2.69和1.81/100患者年(P=0.67)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The vast majority of children with sickle cell anemia (SCA) live in Africa, where evidence-based guidelines for primary stroke prevention are lacking. In Kano, Nigeria, we conducted a feasibility trial to determine the acceptability of hydroxyurea therapy for primary stroke prevention in children with abnormal transcranial Doppler (TCD) measurements. Children with SCA and abnormal non-imaging TCD measurements (≥200 cm/s) received moderate fixed-dose hydroxyurea therapy (∼20 mg/kg/day). A comparison group of children with TCD measurements <200 cm/s was followed prospectively. Approximately 88% (330 of 375) of families agreed to be screened, while 87% (29 of 33) of those with abnormal TCD measurements, enrolled in the trial. No participant elected to withdraw from the trial. The average mean corpuscular volume increased from 85.7 fl at baseline to 95.5 fl at 24 months (not all of the children who crossed over had a 24 month visit), demonstrating adherence to hydroxyurea. The comparison group consisted of initially 210 children, of which four developed abnormal TCD measurements, and were started on hydroxyurea. None of the monthly research visits were missed (n = total 603 visits). Two and 10 deaths occurred in the treatment and comparison groups, with mortality rates of 2.69 and 1.81 per 100 patient-years, respectively (P = .67). Our results provide strong evidence, for high family recruitment, retention, and adherence rates, to undertake the first randomized controlled trial with hydroxyurea therapy for primary stroke prevention in children with SCA living in Africa.
引用
- Galadanci NA, Umar Abdullahi S, Vance LD, et al. Feasibility trial for primary stroke prevention in children with sickle cell anemia in Nigeria (SPIN trial). Am J Hematol. 2017. PMID: 28439953. doi:10.1002/ajh.24770
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。